Jefferies & Co Upgrades Cephalon (CEPH) to Buy
More News related to CEPH
- Notable Mergers and Acquisitions of the Day 02/01: CEPH, SUN/BAK, MDZ/DHR
- Cephalon (CEPH) Will Pay $590M to Acquire Mepha AG
- Cephalon (CEPH) Acquires Mepha AG for $590M
- Cephalon, Inc. Announces Agreement to Acquire Mepha AG
- Cephalon (CEPH) Names Three New Executives
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Jefferies & Co upgrades Cephalon (Nasdaq: CEPH) from Hold to Buy. Price target increased from $58 to $63.
To see all the upgrades/downgrades on shares of CEPH, visit our Analyst Ratings page.
Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in three therapeutic areas: central nervous system (CNS), pain and oncology.
Related Categories
UpgradesStocks Mentioned
+0.78Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
